Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-09EMA Authorised: Kineret (anakinra) — Swedish Orphan Biovitrum AB (publ)
New authorisation of Kineret (anakinra) for rheumatoid arthritis and COVID-19 infection in the EU.
-
EMA approval · 2026-06-09EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.
Avtozma (tocilizumab) has been authorised in the EU for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, and …
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
-
EMA approval · 2026-04-23EMA Authorised: Remsima (infliximab) — Celltrion Healthcare Hungary Kft.
EMA authorised Remsima (infliximab) from Celltrion Healthcare Hungary Kft. for multiple inflammatory diseases including rheumatoid arthritis…
-
EMA approval · 2026-04-23EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-10EMA Authorised: Olumiant (Baricitinib) — Eli Lilly Nederland B.V.
EU authorities authorised Olumiant (baricitinib) for rheumatoid arthritis with decision date 30 March 2026.
-
EMA approval · 2026-04-01EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
EMA authorised RoActemra (tocilizumab) for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, cytokine rel…
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
FDA approval · 2026-03-17FDA Approved: PIROXICAM — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for piroxicam from Unichem Pharmaceuticals (USA), Inc., for the generic product.
-
FDA approval · 2026-03-06FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ XR (tofacitinib) from Pfizer Laboratories Div Pfizer Inc, introducing the extended-r…
-
EMA approval · 2026-03-05EMA Authorised: Simponi (golimumab) — Janssen Cilag International NV
The European Medicines Agency authorised Simponi (golimumab) for multiple inflammatory conditions including rheumatoid arthritis, psoriatic …
-
EMA approval · 2026-02-25EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenil…
-
EMA approval · 2026-02-20EMA Authorised: Kevzara (sarilumab) — Sanofi Winthrop Industrie
The EMA has authorised Kevzara (sarilumab) for rheumatoid arthritis in the European Union.
-
EMA approval · 2026-02-19EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, u…
-
EMA approval · 2026-02-17EMA Authorised: Inflectra (infliximab) — Pfizer Europe MA EEIG
EMA authorised Inflectra (infliximab) as a biosimilar to Remicade for multiple inflammatory diseases including rheumatoid and psoriatic arth…
-
EMA approval · 2026-02-05EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid art…
-
EMA approval · 2026-02-05EMA Authorised: Tocilizumab STADA (previously Tofidence) (tocilizumab) — STADA Arzneimittel AG
EMA authorised STADA's tocilizumab product (Tocilizumab STADA) for rheumatoid arthritis, juvenile idiopathic arthritis, and COVID-19 infecti…
-
EMA approval · 2026-02-04EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.
EMA authorised Imraldi, a biosimilar adalimumab by Samsung Bioepis NL B.V., for multiple inflammatory diseases including ankylosing spondyli…
-
EMA approval · 2026-01-30EMA Authorised: Kineret (anakinra) — Swedish Orphan Biovitrum AB (publ)
EMA authorised Kineret (anakinra) by Swedish Orphan Biovitrum AB (publ) with an expanded indication to include COVID-19 infection in additio…
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
EMA approval · 2026-01-28EMA Authorised: Leflunomide Zentiva (previously Leflunomide Winthrop) (leflunomide) — Zentiva k.s.
The EMA has authorised Leflunomide Zentiva for use in rheumatoid arthritis and psoriatic arthritis.
-
EMA approval · 2026-01-27EMA Authorised: Cimzia (certolizumab pegol) — UCB Pharma
The European Medicines Agency authorised Cimzia (certolizumab pegol) for treatment of rheumatoid arthritis and other inflammatory diseases, …
-
EMA approval · 2026-01-26EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.
EMA has authorized Avtozma, a tocilizumab biosimilar, for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, an…
-
FDA approval · 2026-01-21FDA Approved: CYCLOSPORINE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith's original ANDA for generic cyclosporine.
-
FDA approval · 2026-01-14FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)
FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.